EUCTR2006-005377-22-LT进行中（未招募）不适用
Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with 9 mg budesonide or 3 g mesalazine in patients with active ulcerative colitis - Budesonide capsules versus mesalazine granules in active UC
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent,
- •2. Men or women aged 18 to 75 years,
- •3. Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology,
- •4. Established disease (presence of blood or mucus in the stools) or new diagnosis (bloody stools occurring at least during 14 days prior to baseline visit),
- •5. Clinical Activity Index (CAI) >= 6 and Endoscopical Index (EI) >= 4,
- •6. Women of child-bearing potential, if heterosexually active, have to apply a highly effective method of birth control, which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptive method, some intrauterine devices (IUDs), sexual abstinence, or vasectomised partner. The investigator is responsible for determining whether the subject has adequate birth control for study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),
- •2. Toxic megacolon,
- •3. Baseline stool positive for germs causing bowel disease,
- •4. Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract,
- •5. Active peptic ulcer disease,
- •6. Haemorrhagic diathesis,
- •7. Asthma, diabetes mellitus, infection, osteoporosis, glaucoma, cataract, or cardiovascular disease if careful medical monitoring is not ensured,
- •8. Severe co-morbidity substantially reducing life expectancy,
- •9. Active colorectal cancer or a history of colorectal cancer,
- •10. Active malignancy other than colorectal cancer or treatment with anticancer drugs during the last 5 years. Patients with a history of cancer other than colorectal cancer and at least five years of uneventful follow up and no signs of recurrence may be eligible,
- •11. Immunosuppressants within 3 months and/or corticosteroids (oral, intravenous [IV] or topical rectal) within 4 weeks prior to baseline,
- •12. Current relapse occurred under maintenance treatment with > 2.4 g mesalazine per day,
- •13. Abnormal renal function (Serum Cystatin C > upper limit of normal [ULN]),
- •14. Abnormal hepatic function (ALT, AST or AP >2 x ULN) or liver cirrhosis,
- •15. Known intolerance/hypersensitivity/resistance to study drugs or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the study drugs,
- •16. Doubt about the patient’s cooperation, e.g., because of addiction to alcohol or drugs,
- •17. Existing or intended pregnancy or breast-feeding,
- •18. Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
研究者
相似试验
进行中（未招募）
不适用
A comparative study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitisActive ulcerative colitisMedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-001830-32-LTDr. Falk Pharma GmbH400
进行中（未招募）
1 期
A comparative study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitisActive ulcerative colitisMedDRA version: 15.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-001830-32-LVDr. Falk Pharma GmbH400
进行中（未招募）
不适用
A comparative study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitisActive ulcerative colitisMedDRA version: 16.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-001830-32-PLDr. Falk Pharma GmbH400
进行中（未招募）
不适用
Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with 9 mg budesonide or 3 g mesalazine in patients with active ulcerative colitis - Budesonide capsules versus mesalazine granules in active UCTreatment of ulcerative colitisMedDRA version: 9.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisEUCTR2006-005377-22-CZDr. Falk Pharma GmbH360
进行中（未招募）
1 期
A comparative study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitisActive ulcerative colitisMedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-001830-32-HUDr. Falk Pharma GmbH400